Resources
ULISES has developed a number of useful resources available to the public, from official documents to deliverables, scientific papers, and a set of factsheets.
Take a look at them!
2024
Assessment of the efficacy of a monoclonal antibody against pancreatic tumour cells by complement-dependent cytotoxicity assay”.
POSTER - PDF — 920.15 KB — 11 Oct 2024
The communication poster presented by IMIB-Irraxca on the occasion of their participation in the 7th edition of the European Congress on Immunology in Dublin (1st-4th of September 2024).
DownloadPeptides Derived From Mismatched Paternal Human Leukocyte Antigen Predicted to Be Presented by HLA-DRB1, -DRB3/4/5, -DQ, and -DP Induce Child-Specific Antibodies in Pregnant Women
PAPERS - PDF — 6.10 MB — 27 Aug 2024
The aim of this study is to explore correlations between the numbers of HLA-derived allopeptides presented by different HLA Class II loci and their association with CSA after pregnancy. Based on these analyses, strategies to aggregate PIRCHE-II presented on HLA-DQ and -DP into the so-far DRB1-restricted PIRCHE scores (PSs) are suggested.
DownloadT-Cell Epitopes Shared Between Immunizing HLA and Donor HLA Associate With Graft Failure After Kidney Transplantation
PAPERS - PDF — 3.41 MB — 27 Aug 2024
This study explored the immunogenicity of HLA epitopes and their role in developing T-cell memory. In the concept of linked recognition, CD4+ Helper T cells recognize mismatched HLA and lead to the formation of memory T cells against the HLA antigen. The use of epitope-focused HLA matching tools in the context of kidney transplantation in a large cohort helps to explain how this process works and explores how concepts of linked recognition could be applied in a variety of settings.
DownloadValidation in vitro and in vivo of nanoparticle treatment to induce anti-tumoral alloreactivity
FACTSHEETS - PDF — 275.19 KB — 27 Jun 2024
As part of ULISES, project partner IMIB-Arrixaca has carried out in vitro validation. This involved performing cytotoxicity assays using human pancreatic adenocarcinoma cells (PANC-1). These were transformed with the nanoparticles to express allogeneic Human Leucocyte Antigen (HLA) molecules. For in vivo validation, a tumour-xenotransplant mouse model treated with nanoparticles was used to evaluate anti-tumour alloreactivity. The in vitro results indicate that the transformed cells become vulnerable to the effector mechanisms of the immune system and can be efficiently targeted. The in vivo results are promising, but they will require better therapeutic approaches.
Download